Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $3.45 and traded as low as $3.38. Cryo-Cell International shares last traded at $3.48, with a volume of 7,647 shares trading hands.

Cryo-Cell International Price Performance

The stock has a market capitalization of $28.05 million, a price-to-earnings ratio of -11.60 and a beta of 0.49. The firm has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $3.45.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its earnings results on Wednesday, July 15th. The company reported $0.07 EPS for the quarter. The firm had revenue of $7.78 million during the quarter.

Hedge Funds Weigh In On Cryo-Cell International

A hedge fund recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International as of its most recent SEC filing. 10.44% of the stock is owned by hedge funds and other institutional investors.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.